Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations. by Chuanjiang Yu, Rama Krishna Kancha, Justus Duyster

Get full text

Analysis of conformational determinants underlying HSP90-kinase interaction. by Rama Krishna Kancha, Natalie Bartosch, Justus Duyster

Get full text

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation by Rama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, Christian Peschel, Katharina S. Götze, Justus Duyster

Get full text

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. by Rama Krishna Kancha, Nikolas von Bubnoff, Natalie Bartosch, Christian Peschel, Richard A Engh, Justus Duyster

Get full text

A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance by Sivahari Prasad Gorantla, Tony Andreas Mueller, Corinna Albers‐Leischner, Martina Rudelius, Nikolas vonBubnoff, Justus Duyster

Get full text

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refr... by Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke, Robert Zeiser

Get full text

Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors by Swapna Kamasani, Sravani Akula, Sree Kanth Sivan, Vijjulatha Manga, Justus Duyster, Dashavantha Reddy Vudem, Rama Krishna Kancha

Get full text

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient by Sarolta Bojtine Kovacs, Jingting Luan, Sandra Maria Dold, Andreas Weis, Milena Pantic, Justus Duyster, Ralph Wäsch, Monika Engelhardt

Get full text

FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia by Ines Peschel, Silvio R. Podmirseg, Martin Taschler, Justus Duyster, Katharina S. Götze, Heinz Sill, David Nachbaur, Heidelinde Jäkel, Ludger Hengst

Get full text

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms by Sivahari P. Gorantla, Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff

Get full text

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics by Nora Rebeka Javorniczky, Olga Grishina, Inga Hund, Milena Pantic, Dietmar Pfeifer, Claudia Schmoor, Johanna Thomas, Justus Duyster, Heiko Becker, Michael Lübbert

Get full text

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma by Sandra Maria Dold, Veronika Riebl, Dagmar Wider, Marie Follo, Milena Pantic, Gabriele Ihorst, Justus Duyster, Robert Zeiser, Ralph Wäsch, Monika Engelhardt

Get full text

Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany by Khalid Shoumariyeh, Francesca Biavasco, Gabriele Ihorst, Siegbert Rieg, Alexandra Nieters, Winfried V. Kern, Cornelius Miething, Justus Duyster, Monika Engelhardt, Hartmut Bertz

Get full text

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life by Christine Greil, Monika Engelhardt, Gabriele Ihorst, Katja Schoeller, Hartmut Bertz, Reinhard Marks, Robert Zeiser, Justus Duyster, Hermann Einsele, Jürgen Finke, Ralph Wäsch

Get full text

Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells. by Anna L Illert, Anna K Seitz, Christoph Rummelt, Stefanie Kreutmair, Richard A Engh, Samantha Goodstal, Christian Peschel, Justus Duyster, Nikolas von Bubnoff

Get full text

Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure by Miriam Mozaffari Jovein, Gabriele Ihorst, Jesús Duque-Afonso, Ralph Wäsch, Hartmut Bertz, Claudia Wehr, Justus Duyster, Robert Zeiser, Jürgen Finke, Florian Scherer

Get full text

C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway by Natasa Anastasov, Irina Bonzheim, Martina Rudelius, Margit Klier, Therese Dau, Daniela Angermeier, Justus Duyster, Stefania Pittaluga, Falko Fend, Mark Raffeld, Leticia Quintanilla-Martinez

Get full text

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis by Stefanie Kreutmair, Stefanie Kreutmair, Lena Johanna Lippert, Lena Johanna Lippert, Cathrin Klingeberg, Corinna Albers-Leischner, Corinna Albers-Leischner, Salome Yacob, Valeria Shlyakhto, Tony Mueller, Tony Mueller, Alina Mueller-Rudorf, Chuanjiang Yu, Sivahari Prasad Gorantla, Sivahari Prasad Gorantla, Cornelius Miething, Cornelius Miething, Justus Duyster, Justus Duyster, Anna Lena Illert, Anna Lena Illert

Get full text

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML by Silvia Waldeck, Michael Rassner, Philip Keye, Marie Follo, Dieter Herchenbach, Cornelia Endres, Anne Charlet, Geoffroy Andrieux, Ulrich Salzer, Melanie Boerries, Justus Duyster, Nikolas vonBubnoff

Get full text

Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies. by Susanne Kratzat, Viktoriya Nikolova, Cornelius Miething, Alexander Hoellein, Stephanie Schoeffmann, Oliver Gorka, Elke Pietschmann, Anna-Lena Illert, Jürgen Ruland, Christian Peschel, Jonas Nilsson, Justus Duyster, Ulrich Keller

Get full text